n-leucyldoxorubicin and Breast Neoplasms
n-leucyldoxorubicin has been researched along with Breast Neoplasms in 3 studies
Research
Studies (3)
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 2 (66.67) | 18.2507 |
2000's | 1 (33.33) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors
Authors | Studies |
---|---|
Bennis, S; Garcia, C; Robert, J | 1 |
Berger, DP; Breistøl, K; Fiebig, HH; Fodstad, O; Hendriks, HR; Langdon, SP | 1 |
Abarca-Quinones, J; Baurain, R; Dubois, V; Fernandez, AM; Lobl, TJ; Oliyai, C; Passioukov, A; Shochat, D; Trouet, A; Van derpoorten, K | 1 |
Other Studies
3 other study(ies) available for n-leucyldoxorubicin and Breast Neoplasms
Article | Year |
---|---|
Aspects of the cellular pharmacology of N-l-leucyldoxorubicin in human tumor cell lines.
Topics: Breast Neoplasms; Cell Death; Doxorubicin; Drug Resistance; Humans; Leukemia; Prodrugs; Time Factors; Tumor Cells, Cultured | 1993 |
The antitumour activity of the prodrug N-L-leucyl-doxorubicin and its parent compound doxorubicin in human tumour xenografts.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cell Division; Dose-Response Relationship, Drug; Doxorubicin; Female; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Prodrugs; Transplantation, Heterologous | 1998 |
Extracellularly tumor-activated prodrugs for the selective chemotherapy of cancer: application to doxorubicin and preliminary in vitro and in vivo studies.
Topics: Animals; Antibiotics, Antineoplastic; Biotransformation; Breast Neoplasms; Doxorubicin; Drug Stability; Female; Humans; Lethal Dose 50; Male; Mice; Mice, Inbred BALB C; Oligopeptides; Prodrugs; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2001 |